Search Results
10
Everything
Search Filters
Organization
Medigene AG
Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office
March 13, 2025 09:30 ET
|
Medigene AG
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today...
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
February 27, 2025 03:00 ET
|
Medigene AG
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered...
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
February 19, 2025 05:00 ET
|
Medigene AG
Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided...
Medigene AG announces closing of its first SEPA tranche
February 03, 2025 12:00 ET
|
Medigene AG
Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
December 09, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
December 03, 2024 05:00 ET
|
Medigene AG
Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially...
Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment
November 26, 2024 08:00 ET
|
Medigene AG
Planegg/Martinsried, November 26, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided...
Medigene Presents Data on an Innovative IFN-γ Biosensor Technology at SITC 2024
November 12, 2024 07:00 ET
|
Medigene AG
Planegg/Martinsried, November 12, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Latest Data on UniTope & TraCR Technology at PEGS and SITC 2024
November 11, 2024 07:00 ET
|
Medigene AG
Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
November 08, 2024 09:30 ET
|
Medigene AG
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars...